Status:
COMPLETED
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
Lead Sponsor:
University Hospital, Lille
Conditions:
Depression
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant action of ketamine in palliative care situations. Half of participants will receive Ketamine and Milnacipran...
Detailed Description
Ketamine, a molecule mainly used as an analgesic in palliative care, turns out to be an excellent fast acting antidepressant. By acting as an NMDA receptor antagonist, its mechanism of action is compl...
Eligibility Criteria
Inclusion
- Inpatient
- Supported by a functional palliative care unit
- Having a severe and progressive disease diagnosed
- Meet the criteria for major depressive disorder as defined by DSM in its version 5
- MADRS \> 19 ( moderate to severe)
- No antidepressant treatment or treatment introduced for more than four weeks
- In ability to receive clear information and give consent
- Beneficiary of a social security scheme
Exclusion
- upper weight or equal to 100 kg
- ultimate phase (about 24 to 72 hours prior to death)
- unstable patient on cardiovascular diseases, including uncontrolled hypertension
- severe renal impairment (renal clearance less than 15 ml / min)
- psychiatric comorbidity: schizophrenia and schizoaffective disorder
- neurological comorbidity: recent cerebrovascular accident (Less than one month), Parkinson's disease, dementia
- treatment with ketamine received in the four weeks preceding the inclusion
- impaired judgment, cognitive or massive sensory impairment not allowing to receive clear information
- oral antidepressant treatment introduced less than four weeks ago
- dosage of oral antidepressant treatment upper than the marketing authorization for more than four weeks
- patient not covered by the social security system
- refusal to sign the consent
- minor patient or guardianship
- pregnant women (implementation of a urine pregnancy test before inclusion for women of childbearing age)
- lactating women
- intolerance or allergic reaction to ketamine or milnacipran.
- contraindications to the association of ketamine or milnacipran with the patient's usual treatment
Key Trial Info
Start Date :
September 8 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2024
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT02783430
Start Date
September 8 2016
End Date
March 8 2024
Last Update
December 16 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens Picardie
Amiens, France
2
Ch Calais
Calais, France
3
Maison Medicale Jean Xxiii - Lille
Lille, France, 59037
4
University Hospital,
Lille, France